Form 4: BridgeBio Pharma CEO Reports Stock Transaction
Insider Transaction (Form 4)
Neil Kumar, Chief Executive Officer and a Director of BridgeBio Pharma, Inc., reported multiple transactions in common stock on August 16, 2026.
Summary
- Option exercise/conversion: acquired 33,544 Common Stock on August 16, 2026; holds 276,871 after (Direct).
- Option exercise/conversion: acquired 19,599 Common Stock on August 16, 2026; holds 296,470 after (Direct).
- Option exercise/conversion: acquired 11,554 Common Stock on August 16, 2026; holds 308,024 after (Direct).
- Option exercise/conversion: acquired 6,520 Common Stock on August 16, 2026; holds 314,544 after (Direct).
- Tax/exercise-price withholding: disposed of 36,237 Common Stock at $79.86 ($2,893,887) on August 16, 2026; holds 278,307 after (Direct).
- Option exercise/conversion: disposed of 33,544 Restricted Stock Units on August 16, 2026; holds 67,088 after (Direct).
- Option exercise/conversion: disposed of 19,599 Restricted Stock Units on August 16, 2026; holds 117,596 after (Direct).
- Option exercise/conversion: disposed of 11,554 Restricted Stock Units on August 16, 2026; holds 115,538 after (Direct).
- Option exercise/conversion: disposed of 6,520 Restricted Stock Units on August 16, 2026; holds 91,274 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Neil Kumar — Director, Officer (Chief Executive Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-16 | Option exercise/conversion | Common Stock | 33,544 | — | — | 276,871 |
| 2026-08-16 | Option exercise/conversion | Common Stock | 19,599 | — | — | 296,470 |
| 2026-08-16 | Option exercise/conversion | Common Stock | 11,554 | — | — | 308,024 |
| 2026-08-16 | Option exercise/conversion | Common Stock | 6,520 | — | — | 314,544 |
| 2026-08-16 | Tax/exercise-price withholding | Common Stock | 36,237 | $80 | $2.9M | 278,307 |
| 2026-08-16 | Option exercise/conversion | Restricted Stock Units | 33,544 | — | — | 67,088 |
| 2026-08-16 | Option exercise/conversion | Restricted Stock Units | 19,599 | — | — | 117,596 |
| 2026-08-16 | Option exercise/conversion | Restricted Stock Units | 11,554 | — | — | 115,538 |
| 2026-08-16 | Option exercise/conversion | Restricted Stock Units | 6,520 | — | — | 91,274 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-16 | Option exercise/conversion (33,544 shares) |
| 2026-08-16 | Option exercise/conversion (19,599 shares) |
| 2026-08-16 | Option exercise/conversion (11,554 shares) |
| 2026-08-16 | Option exercise/conversion (6,520 shares) |
| 2026-08-16 | Tax/exercise-price withholding (36,237 shares) |
| 2026-08-16 | Option exercise/conversion (33,544 shares) |
| 2026-08-16 | Option exercise/conversion (19,599 shares) |
| 2026-08-16 | Option exercise/conversion (11,554 shares) |
| 2026-08-16 | Option exercise/conversion (6,520 shares) |
Keywords
insider transaction, Form 4, BBIO, BridgeBio Pharma, Inc., neutral, Neil Kumar
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.